MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2020 Earnings Conference Call - Final Transcript
Sep 09, 2020 • 05:00 pm ET
the Phase 2 study are continuing treatment until Helsinn decides on the status of the overall program. The program status is wholly within the realm of Helsinn's rights under the license agreement and any future steps in the pracinostat program will be at Helsinn's decision. In sum, fiscal 2020 was successful and advancing both key business and clinical objectives particularly regarding our lead candidate zandelisib.
Before opening the call to your questions, I'd like to note some additional developments, including the appointment of Tamar Howson to our board at the beginning of fiscal 2019. Ms. Howson is a highly experienced Business Development Executive with more than 30 years in the industry, including Executive VP of Corporate Business Development at Lexicon, and Senior VP of Corporate and Business Development at BMS.
Finally, as Brian noted earlier, we significantly strengthened our cash position over the course of this year. With the approximate $52 million [Phonetic] from our December 2019 financing, about $21 million in proceeds from our ATM facility and the upfront payment for Kyowa Kirin we started this current fiscal year with about $183 million. Taking into account our current cash, plus the approximate $20 million we expect to receive sometime this year from the Japanese tax authorizes, that's about $203 million on a pro forma basis, which we believe provides a sufficient cash runway to see us through at least 2023.
In terms of upcoming milestones, we expect, most importantly, completion of enrollment in TIDAL and top line data. The initiation of the marginal zone arm in TIDAL, initiation of a Phase 2 Japan study by Kyowa Kirin, initiation of a confirmatory Phase 3 study in follicular lymphoma, zandelisib and zanubrutinib combination data, zandelisib NDA submission for accelerated approval in follicular lymphoma, voruciclib data from our ongoing studies, all the while we build out our commercial infrastructure to be prepared for potential zandelisib launch.
As is evidence from our milestones just mentioned, to maximize our success, we intend to primarily apply our resources, our efforts and our focus to zandelisib in order to fully optimize its potential to deliver benefits to patients and value to our investors. All the while, while we explore the potential utility of our other pipeline candidates.
With that update, I think we are now ready for questions. Operator?